Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

71.24
-0.6100-0.85%
Post-market: 71.21-0.0300-0.04%16:47 EDT
Volume:907.28K
Turnover:65.06M
Market Cap:7.55B
PE:62.36
High:73.13
Open:72.04
Low:70.78
Close:71.85
Loading ...

Corcept Therapeutics Incorporated Held Annual Stockholders Meeting

Reuters
·
17 Jun

William Guyer, Chief Development Officer, Reports Disposal of Common Shares in Corcept Therapeutics Inc

Reuters
·
13 Jun

Analysts Conflicted on These Healthcare Names: Corcept Therapeutics (CORT), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
12 Jun

Corcept Therapeutics Says Its ALS Drug Candidate Fails to Meet Primary Goal

MT Newswires Live
·
05 Jun

Corcept Presents Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) at Encals 2025 Annual Meeting

THOMSON REUTERS
·
05 Jun

Corcept Therapeutics Inc - Dazals Study Did Not Meet Primary Endpoint

THOMSON REUTERS
·
05 Jun

Joseph Douglas Lyon, Officer, Reports Disposal of Common Shares of Corcept Therapeutics Incorporated

Reuters
·
05 Jun

Buy Rating for Corcept Therapeutics Based on Promising Phase III ROSELLA Study Results

TIPRANKS
·
03 Jun

Promising ROSELLA Study Boosts Buy Rating for Corcept Therapeutics with Relacorilant’s Potential in Ovarian Cancer Treatment

TIPRANKS
·
03 Jun

Corcept Therapeutics Says Relacorilant Met Primary Endpoint in Phase 3 Ovarian Cancer Trial

MT Newswires Live
·
02 Jun

Corcept Therapeutics says Phase 3 ROSELLA trial met primary endpoint

TIPRANKS
·
02 Jun

Top Executive Sells Thousands in Corcept Therapeutics Stock!

TIPRANKS
·
23 May

Chief Business Officer Gary Charles Robb Reports Disposal of Common Shares in Corcept Therapeutics Inc

Reuters
·
23 May

Director’s Major Stock Sale Shakes Up Corcept Therapeutics

TIPRANKS
·
21 May

William Guyer, Chief Development Officer, Reports Disposal of Common Shares of Corcept Therapeutics Inc

Reuters
·
21 May

Stock Track | Corcept Therapeutics Plummets 9% on Analyst Downgrades and Insider Selling

Stock Track
·
06 May

Truist Cuts Price Target on Corcept Therapeutics to $135 From $150, Keeps Buy Rating

MT Newswires Live
·
06 May

Stock Track | Corcept Therapeutics Plunges 5.33% Pre-Market Amid Insider Selling and Analyst Price Target Cuts

Stock Track
·
06 May

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
06 May

Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT)

TIPRANKS
·
06 May